Ignite Creation Date:
2024-05-06 @ 6:40 PM
Last Modification Date:
2024-10-26 @ 2:52 PM
Study NCT ID:
NCT05743634
Status:
COMPLETED
Last Update Posted:
2023-02-24
First Post:
2023-02-15
Brief Title:
A Phase III Study of Recombinant Botulinum Toxin Type A for the Treatment of Moderate to Severe Glabellar Lines
Sponsor:
Chongqing Claruvis Pharmaceutical Co Ltd
Organization:
Chongqing Claruvis Pharmaceutical Co Ltd
Study Overview
Official Title:
A Phase IIIMulticenter Randomized Double-Blind Placebo and Active-Controlled Study to Evaluate the SafetyEfficacy and Immunogenicity of Recombinant Botulinum Toxin Type A for the Treatment of Moderate to Severe Glabellar Lines
Status:
COMPLETED
Status Verified Date:
2023-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a phase 12 multicenter randomized double-blind active-controlled and placebo-controlled study to evaluate safetyimmunogenicity and efficacy of YY001 for the treatment of moderate to severe glabellar lines in male and female subjects of Chinese origin The study has been designed to test the safetyefficacyimmunogenicity of YY001and compare to onabotulinumtoxinA BOTOX and placebo in improving the appearance of moderate to severe glabellar lines
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CTR20221419 | REGISTRY | wwwchinadrugtrialsorgcn | None |